Search results
Results from the WOW.Com Content Network
DPP-4 inhibitors and GLP-1. Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins) are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2. The first agent of the class – sitagliptin – was approved by the FDA in 2006. [1]
Aromatic heterocyclic-based DPP-4 inhibitors have gained increased attention recently. The first patents describing xanthines (Figure 10) as DPP-4 inhibitors came from Boehringer-Ingelheim(BI) and Novo Nordisk. [21] When xanthine based DPP-4 inhibitors are compared with sitagliptin and vildagliptin it has shown a superior profile.
Pages in category "Dipeptidyl peptidase-4 inhibitors" The following 22 pages are in this category, out of 22 total. This list may not reflect recent changes. ...
Linagliptin is a dipeptidyl peptidase-4 inhibitor [8] that works by increasing the production of insulin and decreasing the production of glucagon by the pancreas. [ 8 ] Linagliptin was approved for medical use in the United States, [ 11 ] Japan, the European Union, Canada, and Australia in 2011.
All of those patients were either taking oral diabetes medications SGLT-2 or DPP-4 inhibitors for their condition. SGLT-2 helps the kidneys remove excess glucose from the body through urine, while ...
Alogliptin, sold under the brand names Nesina and Vipidia, [2] [3] is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. [4] Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. [1]
Generally, drugs outlined within the ATC code A10 should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Anti-diabetic drugs .
Medications based on incretins are used in the treatment of type 2 diabetes mellitus as well as the management of obesity.. Most of the earliest incretin-targeting agents to be approved fell into the class of DPP-4 inhibitors; these inhibit DPP-4 and thus prevent the enzymatic degradation of GLP-1 and GIP.